Dare Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Dare Bioscience, Inc. on August 9, 2022. The report serves to announce the company's financial results for the second quarter ended June 30, 2022. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol DARE.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K acts as a notification that a press release containing these details has been issued. The specific financial data is contained in Exhibit 99.1 (the press release), which is furnished but not included in the text of this summary.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the text provided. It references the Q2 2022 results announcement but does not quantify year-over-year or quarter-over-quarter performance metrics.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These elements are referenced as being part of the press release (Exhibit 99.1) but are not present in the 8-K body text.
Key Facts for Investor Verification
- Verify the specific Q2 2022 financial results (revenue, net loss, cash position) in the press release dated August 9, 2022 (Exhibit 99.1).
- Confirm the company's cash runway and burn rate as disclosed in the referenced press release.
- Review the press release for any updates on clinical trial progress or regulatory milestones for the company's product candidates.
- Note that the information in this 8-K is furnished and not filed for purposes of Section 18 of the Exchange Act.